Nasdaq
$134.00▲ 1.16%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.75BShares out 42.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 10.16After-hours26.10.17 05:504Ownership#●●●#●●●
GRAIL, Inc.
Gregory L. Summe, a director at GRAIL, Inc., reported changes in his beneficial ownership of securities via a Form 4 filing on October 15, 2026. This filing reflects shifts in the equity holdings of the company's leadership and board members.…more
$134.00+1.16%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.16After-hours26.10.17 05:504Ownership
GRAIL, Inc.
GRAIL, Inc. insider William J. Chase filed a Form 4 report on October 16, 2026, regarding changes in beneficial ownership of securities as of October 15, 2026. This filing serves as a standard disclosure of executive equity transactions.…more
$134.00+1.16%vs prev closeView filingShare - 10.16After-hours26.10.17 05:504Ownership
GRAIL, Inc.
Insider Joshua J. Ofman of GRAIL, Inc. filed a Form 4 on October 15, 2026, reporting changes in beneficial ownership of securities. This filing reflects updates regarding executive stock holdings.…more
$134.00+1.16%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.5After-hours26.10.06 05:02#●●●#●●●
GRAIL to Present New NHS-Galleri Trial Data at Upcoming Medical Conferences…more
GRAIL will present new data from its NHS-Galleri clinical trial at the Early Detection of Cancer Conference and ESMO Congress. These findings are expected to provide further insights into the effectiveness of their cancer detection technology.…more
$134.00+1.16%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.24Regular26.09.25 02:27
●●●●●●●● ●●●●● ●●●●●●
GRAIL's multi-cancer early detection test, Galleri, received a positive recommendation from an FDA advisory panel regarding its safety and efficacy. The panel concluded that the benefits of the test for adults aged 50 and older outweigh its potential risks.…more
$134.00+1.16%vs prev closeShareBenzinga - 9.24Pre-market26.09.24 20:00
●●●●●●●● ●●●●● ●●●●●●
The trading halt status for the stock has been updated with specific details regarding news and the resumption time. Investors should review the official announcement to confirm when trading will resume.…more
$134.00+1.16%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report